Hydrasec (Racecadotril) Indications in Pediatric Patients
Hydrasec (racecadotril) is indicated as adjunctive therapy to oral rehydration solution for the symptomatic treatment of acute diarrhea in children aged 3 months and older.
Primary Indication
Racecadotril serves as an antisecretory adjunct to oral rehydration therapy in managing acute watery diarrhea in the pediatric population. The drug works by inhibiting neutral endopeptidase (NEP), which allows enkephalins to reduce water and electrolyte hypersecretion in the small intestine without affecting intestinal motility 1.
Key Clinical Context
While the 2017 IDSA guidelines note that racecadotril reduces stool volume, they explicitly state it is not available in North America and do not provide specific recommendations for its use 2. This creates a geographic limitation on its clinical application in the United States.
Evidence-Based Benefits
When used appropriately, racecadotril demonstrates:
- 46-50% reduction in stool output within the first 48 hours 3, 4
- Shortened duration of diarrhea (median 28 hours vs 52-72 hours with placebo) 3
- Reduced need for emergency department visits and hospitalizations 5
- Decreased oral rehydration solution requirements 3
- Efficacy regardless of rotavirus status 3, 4
Critical Limitations and Caveats
Important: A 2019 Cochrane systematic review concluded that racecadotril "has little benefit in improving acute diarrhea in children under five years of age" and stated that "current evidence does not support routine use of racecadotril in management of acute diarrhea in children under five outside of the context of placebo controlled RCTs" 6. This represents the most recent high-quality systematic evidence and contradicts earlier individual trials.
Age Restrictions
- Minimum age: 3 months 7
- The FDA labeling states "children under 12 years old, consult a doctor" 8, though this appears to reference a different formulation
Contraindications
- Do not use if allergic to any ingredients 8
- Pregnancy/nursing requires consultation with healthcare professional 8
Clinical Algorithm for Use
Step 1: Confirm acute watery diarrhea (not bloody, not inflammatory)
- Avoid in suspected inflammatory diarrhea or fever suggesting bacterial infection 2
Step 2: Ensure adequate hydration status first
- Racecadotril is never a substitute for fluid and electrolyte therapy 2
- Initiate oral rehydration solution as primary treatment
Step 3: Consider racecadotril as adjunct only if:
- Child is ≥3 months old
- Diarrhea is watery (not bloody)
- No signs of severe dehydration requiring IV fluids
- Available in your geographic region (not North America)
Step 4: Dosing
Safety Profile
Racecadotril demonstrates good tolerability with only mild, transient adverse effects reported 3, 4. Unlike loperamide, which is contraindicated in children <18 years due to risk of ileus, abdominal distension, lethargy, and death (0.54% mortality in children <3 years) 2, racecadotril does not affect intestinal motility and carries no such risks.
Bottom Line
Despite individual trial evidence showing benefit, the most recent systematic review questions routine clinical use 6. If used, racecadotril should be reserved as an adjunct to—never a replacement for—oral rehydration therapy in children ≥3 months with acute watery diarrhea, primarily in regions where it is approved and available.